These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8380424)

  • 1. Quinolones and macrolides: roles in respiratory infections.
    Khan FA
    Hosp Pract (Off Ed); 1993 Jan; 28(1):149-153, 156-62. PubMed ID: 8380424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Have we reached the point of no return? The hidden impact of antibacterial resistance in respiratory tract infection. Introduction.
    Craig WA
    Respir Med; 2001 Jun; 95 Suppl A():S2-4; discussion S26-7. PubMed ID: 11419670
    [No Abstract]   [Full Text] [Related]  

  • 3. Advances in the macrolides and quinolones.
    Boswell FJ; Wise R
    Infect Dis Clin North Am; 1998 Sep; 12(3):647-70. PubMed ID: 9779383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A guide to the treatment of lower respiratory tract infections.
    Vogel F
    Drugs; 1995 Jul; 50(1):62-72. PubMed ID: 7588090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New and future antibiotics in the treatment of acute respiratory tract infections.
    Wise R
    Thorax; 1995 Mar; 50(3):223-4. PubMed ID: 7660331
    [No Abstract]   [Full Text] [Related]  

  • 6. [In vitro comparative activity of moxifloxacin and other antimicrobials against respiratory pathogens].
    Prado V; Giangrieco M; Durán C; Ojeda A; van Flaskamp R
    Rev Med Chil; 2000 Dec; 128(12):1319-26. PubMed ID: 11227240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quinolones in the treatment of lower respiratory tract infections in adult patients.
    Carbon C
    Drugs; 1993; 45 Suppl 3():91-7. PubMed ID: 7689458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical problems of bacterial resistance to the new quinolones.
    Acar JF; Francoual S
    J Antimicrob Chemother; 1990 Oct; 26 Suppl B():207-13. PubMed ID: 2175305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Alexander Project: using in-vitro susceptibility data for choosing empirical therapy in LRTI.
    Grüneberg RN
    J Antimicrob Chemother; 1996 Jul; 38 Suppl A():155-70. PubMed ID: 8858481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Recent drug administration methods for respiratory infections].
    Matsumoto K; Iwagaki A
    Nihon Naika Gakkai Zasshi; 1991 May; 80(5):675-80. PubMed ID: 1651973
    [No Abstract]   [Full Text] [Related]  

  • 11. The in-vitro antibiotic susceptibility of Chlamydia pneumoniae.
    Fenelon LE; Mumtaz G; Ridgway GL
    J Antimicrob Chemother; 1990 Dec; 26(6):763-7. PubMed ID: 2081718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From fluoroquinolones to 2-pyridones.
    Hooper DC
    Lancet; 1995 May; 345(8959):1192-3. PubMed ID: 7739303
    [No Abstract]   [Full Text] [Related]  

  • 13. Potential improvements in therapeutic options for mycoplasmal respiratory infections.
    Bébéar C; Dupon M; Renaudin H; de Barbeyrac B
    Clin Infect Dis; 1993 Aug; 17 Suppl 1():S202-7. PubMed ID: 8399917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro susceptibility of tetracycline-resistant strains of Ureaplasma urealyticum to newer macrolides and quinolones, and a streptogramin.
    Renaudin H; Bébéar C; Robertson JA
    Eur J Clin Microbiol Infect Dis; 1991 Nov; 10(11):984-6. PubMed ID: 1794374
    [No Abstract]   [Full Text] [Related]  

  • 15. [Pharmacodynamic assessment of antibiotic sensitivity of Streptococcus pneumoniae].
    Soriano F
    Med Clin (Barc); 1999 Jun; 113(3):103-8. PubMed ID: 10464745
    [No Abstract]   [Full Text] [Related]  

  • 16. The activity of grepafloxacin against respiratory pathogens in the UK.
    Wise R; Andrews JM
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():27-30. PubMed ID: 9484870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemifloxacin: survival of the fittest.
    Mandell L
    J Antimicrob Chemother; 2000 Jul; 46 Suppl T1():33-7. PubMed ID: 10997597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Grepafloxacin in respiratory tract infections: are we ready to accept a quinolone for empirical treatment?
    Norrby SR
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():99-101. PubMed ID: 9484879
    [No Abstract]   [Full Text] [Related]  

  • 19. Susceptibility of ninety-eight clinical isolates of Legionella to macrolides and quinolones using the Etest.
    Schrock J; Hackman BA; Plouffe JF
    Diagn Microbiol Infect Dis; 1997 Aug; 28(4):221-3. PubMed ID: 9327252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Refractory respiratory tract infections. 7. Trends in the development of new chemotherapeutic agents for respiratory tract infections. b. Synthetic antibacterial agents].
    Ohno I; Ida S
    Nihon Rinsho; 1987 Mar; 45(3):577-82. PubMed ID: 3298736
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.